Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMPS NASDAQ:CNTA NASDAQ:MIRM NASDAQ:PTCT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPSCompass Pathways$11.79-2.4%$9.71$2.25▼$14.76$1.63B2.53.97 million shs2.07 million shsCNTACentessa Pharmaceuticals$39.76+0.1%$39.64$12.05▼$40.26$6.14B1.111.15 million shs1.61 million shsMIRMMirum Pharmaceuticals$101.00+1.7%$98.02$47.89▼$114.99$6.06B0.5678,885 shs832,595 shsPTCTPTC Therapeutics$76.77+2.2%$70.72$43.17▼$87.50$6.23B0.551.10 million shs3.59 million shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPSCompass Pathways-2.40%+0.51%+13.69%+94.55%+168.56%CNTACentessa Pharmaceuticals+0.10%+0.15%+0.43%+37.34%+221.16%MIRMMirum Pharmaceuticals+1.66%+7.93%-1.15%+4.61%+103.51%PTCTPTC Therapeutics+2.17%+8.33%+7.42%+13.82%+49.77%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPSCompass Pathways$11.79-2.4%$9.71$2.25▼$14.76$1.63B2.53.97 million shs2.07 million shsCNTACentessa Pharmaceuticals$39.76+0.1%$39.64$12.05▼$40.26$6.14B1.111.15 million shs1.61 million shsMIRMMirum Pharmaceuticals$101.00+1.7%$98.02$47.89▼$114.99$6.06B0.5678,885 shs832,595 shsPTCTPTC Therapeutics$76.77+2.2%$70.72$43.17▼$87.50$6.23B0.551.10 million shs3.59 million shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPSCompass Pathways-2.40%+0.51%+13.69%+94.55%+168.56%CNTACentessa Pharmaceuticals+0.10%+0.15%+0.43%+37.34%+221.16%MIRMMirum Pharmaceuticals+1.66%+7.93%-1.15%+4.61%+103.51%PTCTPTC Therapeutics+2.17%+8.33%+7.42%+13.82%+49.77%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMPSCompass Pathways 2.93Moderate Buy$21.3681.20% UpsideCNTACentessa Pharmaceuticals 2.21Hold$41.333.96% UpsideMIRMMirum Pharmaceuticals 2.93Moderate Buy$139.8038.42% UpsidePTCTPTC Therapeutics 2.71Moderate Buy$91.3619.00% UpsideCurrent Analyst Ratings BreakdownLatest CMPS, PTCT, CNTA, and MIRM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/15/2026MIRMMirum Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/15/2026MIRMMirum Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/15/2026MIRMMirum Pharmaceuticals CLSASubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$146.006/15/2026MIRMMirum Pharmaceuticals Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$140.00 ➝ $146.006/11/2026MIRMMirum Pharmaceuticals Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$140.00 ➝ $150.006/9/2026PTCTPTC Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$75.00 ➝ $108.006/8/2026MIRMMirum Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D)6/2/2026MIRMMirum Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform ➝ Buy$145.006/1/2026CMPSCompass Pathways TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/1/2026MIRMMirum Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/27/2026PTCTPTC Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$76.00 ➝ $85.00(Data available from 6/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMPSCompass PathwaysN/AN/AN/AN/A($0.55) per shareN/ACNTACentessa Pharmaceuticals$15M409.95N/AN/A$3.92 per share10.14MIRMMirum Pharmaceuticals$521.31M11.81$0.05 per share1,948.74$6.12 per share16.50PTCTPTC Therapeutics$1.73B3.68$8.97 per share8.56($2.56) per share-29.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMPSCompass Pathways-$287.86M-$3.15N/AN/AN/AN/A-31.07%-11.40%7/30/2026 (Estimated)CNTACentessa Pharmaceuticals-$197.53M-$1.79N/AN/AN/AN/A-60.37%-44.17%8/11/2026 (Estimated)MIRMMirum Pharmaceuticals-$23.36M-$13.61N/A439.13N/A-140.24%-11.28%-3.84%7/30/2026 (Estimated)PTCTPTC Therapeutics$682.64M-$2.33N/A36.383.46-22.58%-362.45%-6.76%8/6/2026 (Estimated)Latest CMPS, PTCT, CNTA, and MIRM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026CMPSCompass Pathways-$0.45-$0.30+$0.15-$0.30N/AN/A5/7/2026Q1 2026PTCTPTC Therapeutics-$0.45-$0.03+$0.42-$0.03$217.42 million$272.55 million5/6/2026Q1 2026MIRMMirum Pharmaceuticals-$0.75-$13.43-$12.68-$13.43$148.21 million$159.88 million5/5/2026Q1 2026CNTACentessa Pharmaceuticals-$0.38-$0.52-$0.14-$0.52N/AN/A3/31/2026Q4 2025CNTACentessa Pharmaceuticals-$0.38-$0.48-$0.10-$0.48$0.77 millionN/A3/24/2026Q4 2025CMPSCompass Pathways-$0.41-$1.00-$0.59-$1.00N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCMPSCompass PathwaysN/AN/AN/AN/AN/ACNTACentessa PharmaceuticalsN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMPSCompass Pathways0.153.323.32CNTACentessa Pharmaceuticals0.239.539.53MIRMMirum Pharmaceuticals1.282.091.99PTCTPTC TherapeuticsN/A2.442.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMPSCompass Pathways46.19%CNTACentessa Pharmaceuticals82.01%MIRMMirum PharmaceuticalsN/APTCTPTC TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipCMPSCompass Pathways2.82%CNTACentessa Pharmaceuticals4.09%MIRMMirum Pharmaceuticals8.32%PTCTPTC Therapeutics5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMPSCompass Pathways120134.95 million131.14 millionOptionableCNTACentessa Pharmaceuticals200154.66 million148.34 millionOptionableMIRMMirum Pharmaceuticals14060.98 million55.91 millionOptionablePTCTPTC Therapeutics1,41082.95 million78.39 millionOptionableCMPS, PTCT, CNTA, and MIRM HeadlinesRecent News About These CompaniesPTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible NotesJune 15 at 11:14 PM | prnewswire.comPTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible NotesJune 15 at 7:00 AM | prnewswire.comInsider Selling: PTC Therapeutics (NASDAQ:PTCT) Insider Sells $1,595,775.00 in StockJune 15 at 4:13 AM | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) Insider Sells $1,595,775.00 in StockJune 13 at 7:02 AM | insidertrades.com96,860 Shares in PTC Therapeutics, Inc. $PTCT Acquired by Castleark Management LLCJune 13 at 3:29 AM | marketbeat.comSector Gamma AS Sells 56,189 Shares of PTC Therapeutics, Inc. $PTCTJune 12, 2026 | marketbeat.comLos Angeles Capital Management LLC Has $2.46 Million Stock Position in PTC Therapeutics, Inc. $PTCTJune 10, 2026 | marketbeat.comPTC Therapeutics, Inc. (PTCT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 9, 2026 | seekingalpha.com19,877 Shares in PTC Therapeutics, Inc. $PTCT Purchased by Commonwealth of Pennsylvania Public School Empls Retrmt SYSJune 8, 2026 | marketbeat.comWhy The PTC Therapeutics (PTCT) Story Is Shifting As Sephience Assumptions Drive New ValuationsJune 7, 2026 | finance.yahoo.comBI Asset Management Fondsmaeglerselskab A S Purchases 64,472 Shares of PTC Therapeutics, Inc. $PTCTJune 7, 2026 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Rating of "Moderate Buy" from BrokeragesJune 7, 2026 | marketbeat.comGeode Capital Management LLC Boosts Stake in PTC Therapeutics, Inc. $PTCTJune 5, 2026 | marketbeat.comBNP Paribas Financial Markets Has $62.95 Million Stock Holdings in PTC Therapeutics, Inc. $PTCTJune 2, 2026 | marketbeat.comLegal & General Group Plc Buys 124,923 Shares of PTC Therapeutics, Inc. $PTCTJune 1, 2026 | marketbeat.comPTC Therapeutics, Inc. $PTCT Shares Sold by Hillsdale Investment Management Inc.May 31, 2026 | marketbeat.comJupiter Asset Management Ltd. Makes New $27.43 Million Investment in PTC Therapeutics, Inc. $PTCTMay 30, 2026 | marketbeat.comRoyce & Associates LP Increases Stock Holdings in PTC Therapeutics, Inc. $PTCTMay 30, 2026 | marketbeat.comPTC Therapeutics upgraded at Jefferies on SephienceMay 27, 2026 | msn.comPTC Therapeutics (NASDAQ:PTCT) Upgraded at Jefferies Financial GroupMay 27, 2026 | marketbeat.comPTC Therapeutics, Inc. $PTCT Position Raised by Jefferies Financial Group Inc.May 24, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 20263 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPOBy Ryan Hasson | May 20, 2026Mirum Pharma: A Rare Disease Growth Story to WatchBy Chris Markoch | May 20, 2026CMPS, PTCT, CNTA, and MIRM Company DescriptionsCompass Pathways NASDAQ:CMPS$11.79 -0.29 (-2.40%) Closing price 06/15/2026 04:00 PM EasternExtended Trading$11.76 -0.03 (-0.30%) As of 06:40 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Compass Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to Compass Pathways plc in August 2020. Compass Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.Centessa Pharmaceuticals NASDAQ:CNTA$39.76 +0.04 (+0.10%) Closing price 06/15/2026 04:00 PM EasternExtended Trading$39.76 0.00 (0.00%) As of 06/15/2026 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.Mirum Pharmaceuticals NASDAQ:MIRM$101.00 +1.65 (+1.66%) Closing price 06/15/2026 04:00 PM EasternExtended Trading$101.60 +0.61 (+0.60%) As of 06:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.PTC Therapeutics NASDAQ:PTCT$76.77 +1.63 (+2.17%) Closing price 06/15/2026 04:00 PM EasternExtended Trading$76.85 +0.08 (+0.10%) As of 06:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas What's Behind the Social Media Controversy Surrounding IonQ? Mission Control: Floating In SpaceX's Record-Breaking Orbit 3 Dividend Increases Investors Can Actually Trust RH’s Strong Q1 Still Leaves Investors With One Big Question SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
